Q2 2026 revenue rose 21% YoY to US $247M, with Precision Medicine up 30% YoY. Strategic collaboration with Regeneron and expanded global operations support guidance for FY 2026 revenue and other income to exceed US $1B.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.